<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01071239</url>
  </required_header>
  <id_info>
    <org_study_id>FA 08/89</org_study_id>
    <nct_id>NCT01071239</nct_id>
  </id_info>
  <brief_title>Hematopoietic Stem Cell Transplant for Fanconi Anemia</brief_title>
  <acronym>FA</acronym>
  <official_title>A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial proposed is a single arm phase II treatment protocol designed to examine
      engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival
      following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine
      and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune
      system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia
      (SAA), or myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML), lacking
      HLA-genotypically identical donors using stem cell transplants derived from (1)
      HLA-compatible unrelated donors or (2) HLA haplotype-mismatched related donors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are currently recruiting patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 30, 2016</completion_date>
  <primary_completion_date type="Actual">August 30, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To measure the incidence and quality of engraftment and hematopoietic reconstitution.</measure>
    <time_frame>1, 3, 6 and 12 months post transplant date</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of early transplant related mortality and incidence and severity of acute and chronic GVHD</measure>
    <time_frame>weekly for the first 30 days and then 3, 6, and 12 months post transplant date</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Fanconi Anemia</condition>
  <arm_group>
    <arm_group_label>Bone marrow processing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bone Marrow processing using the CliniMACs device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACs device</intervention_name>
    <description>Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device</description>
    <arm_group_label>Bone marrow processing</arm_group_label>
    <other_name>Milteny Biotec CliniMACS device</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Chemotherapy administered as a part of the HSCT conditioning regimen.</description>
    <arm_group_label>Bone marrow processing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy administered as a part of the HSCT conditioning regimen.</description>
    <arm_group_label>Bone marrow processing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy administered as a part of the HSCT conditioning regimen.</description>
    <arm_group_label>Bone marrow processing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>Chemotherapy administered as a part of the HSCT conditioning regimen.</description>
    <arm_group_label>Bone marrow processing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fanconi Anemia (confirmed by mitomycin C or DEB chromosomal breakage testing and one
             of the following hematological diagnoses: Severe Aplastic Anemia, Myelodysplastic
             Syndrome, Acute Myelogenous Leukemia

          -  Karnofsky or Lansy performance scale &gt; or = to 70%.

          -  Must have adequate cardiac, hepatic, renal and pulmonary function.

          -  Must have 7/8 or 8/8 available unrelated donor.

        Exclusion Criteria:

          -  Pregnant or breastfeeding.

          -  Active CNS leukemic involvement

          -  Active uncontrolled viral, bacterial or fungal infection

          -  Positive for HIV.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Margolis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <disposition_first_submitted>March 20, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 23, 2018</disposition_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>David A. Margolis</investigator_full_name>
    <investigator_title>Professor of Pediatrics and BMT Program Director</investigator_title>
  </responsible_party>
  <keyword>Fanconi Anemia</keyword>
  <keyword>Hematopoietic stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

